A number of studies have investigated the emergence of discontinuation symptoms following withdrawal selective serotonin reuptake inhibitors.4 Longer use of paroxetine has been associated with increased risk of withdrawal symptoms.4
References:
1. Mann AM, Macpherson AS. Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatr Assoc J 1959; 4 (1): 38–47.
2. Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42 (6): 757–763.
3. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44 (2): 77–87.
4. Jauhar S, Hayes J, Goodwin GM, et al. Antidepressants, withdrawal, and addiction; where are we now? J Psychopharmacol 2019; 33 (6): 655–659.
5. Henssler J, Schmidt Y, Schmidt U, et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry 2024; 11 (7): 526–535.
6. Vinkers CH, Kupka RW, Penninx BW, et al. Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Mol Psychiatry 2024; 29 (8): 2575–2586.
